
    
      This will be a multi-centre, double-blind, randomized, placebo-controlled clinical trial. A
      total of 80 patients with Friedreich's ataxia will be enrolled. Eligible patients will
      receive deferiprone oral solution or placebo at a total daily dose of 20 mg/kg/day, 40
      mg/kg/day or 60 mg/kg/day, divided into two-daily doses for 6 months.
    
  